M2I-1 disrupts the in vivo interaction between CDC20 and MAD2 and increases the sensitivities of cancer cell lines to anti-mitotic drugs via MCL-1s

BACKGROUND: Drugs such as taxanes, epothilones, and vinca alkaloids are widely used in the treatment of breast, ovarian, and lung cancers but come with major side effects such as neuropathy and loss of neutrophils and as single agents have a lack of efficacy. M2I-1 (MAD2 inhibitor-1) has been shown...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianquan, Dang, Nanmao, Martinez-Lopez, Nuria, Jowsey, Paul A., Huang, Dong, Lightowlers, Robert N., Gao, Fei, Huang, Jun-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570884/
https://www.ncbi.nlm.nih.gov/pubmed/31249607
http://dx.doi.org/10.1186/s13008-019-0049-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570884/
https://www.ncbi.nlm.nih.gov/pubmed/31249607
http://dx.doi.org/10.1186/s13008-019-0049-5

Ejemplares similares